These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 16707778)

  • 41. Monitoring treatment and managing adherence in schizophrenia.
    Marder SR
    J Clin Psychiatry; 2013 Oct; 74(10):e21. PubMed ID: 24229761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
    Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF
    Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient outcomes within schizophrenia treatment: a look at the role of long-acting injectable antipsychotics.
    Bera RB
    J Clin Psychiatry; 2014; 75 Suppl 2():30-3. PubMed ID: 24919169
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medication adherence studies in schizophrenia.
    Hogarty GE
    Am J Psychiatry; 2004 Mar; 161(3):581-2; author reply 582-3. PubMed ID: 14992994
    [No Abstract]   [Full Text] [Related]  

  • 45. [Psychopharmocotherapy of schizophrenia in forensic and general psychiatry].
    Stompe T; Schanda H
    Neuropsychiatr; 2011; 25(2):75-84. PubMed ID: 21672506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.
    Brain C; Allerby K; Sameby B; Quinlan P; Joas E; Karilampi U; Lindström E; Eberhard J; Burns T; Waern M
    Eur Neuropsychopharmacol; 2013 Dec; 23(12):1754-62. PubMed ID: 24091164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data.
    Rijcken CA; Tobi H; Vergouwen AC; de Jong-van den Berg LT
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):365-70. PubMed ID: 15170765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
    Schanda H; Stompe T
    Neuropsychiatr; 2010; 24(1):14-26. PubMed ID: 20146916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improving treatment adherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A virtual reality apartment as a measure of medication management skills in patients with schizophrenia: a pilot study.
    Kurtz MM; Baker E; Pearlson GD; Astur RS
    Schizophr Bull; 2007 Sep; 33(5):1162-70. PubMed ID: 16956984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.
    Beck EM; Cavelti M; Kvrgic S; Kleim B; Vauth R
    Schizophr Res; 2011 Oct; 132(1):42-9. PubMed ID: 21820875
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing adherence to dermatology treatments: a review of self-report and electronic measures.
    Greenlaw SM; Yentzer BA; O'Neill JL; Balkrishnan R; Feldman SR
    Skin Res Technol; 2010 May; 16(2):253-8. PubMed ID: 20456106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection.
    Chang CL; Tzeng DS; Lung FW
    Psychiatry Res; 2010 Nov; 180(1):16-9. PubMed ID: 20488552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Adherence to neuroleptic treatment of schizophrenic patients].
    Blondiaux I; Alagille M; Ginestet D
    Encephale; 1988; 14(6):431-8. PubMed ID: 2906607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risks versus benefits of different types of long-acting injectable antipsychotics.
    McEvoy JP
    J Clin Psychiatry; 2006; 67 Suppl 5():15-8. PubMed ID: 16822092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A prototype approach toward antipsychotic medication adherence in schizophrenia.
    Freudenreich O; Tranulis C
    Harv Rev Psychiatry; 2009; 17(1):35-40. PubMed ID: 19205965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia.
    Citrome L
    CNS Spectr; 2012 Nov; 17 Suppl 1():1-9. PubMed ID: 23448847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia.
    Diaz E; Levine HB; Sullivan MC; Sernyak MJ; Hawkins KA; Cramer JA; Woods SW
    J Psychiatry Neurosci; 2001 Sep; 26(4):325-9. PubMed ID: 11590972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia.
    Velligan D; Mintz J; Maples N; Xueying L; Gajewski S; Carr H; Sierra C
    Schizophr Bull; 2013 Sep; 39(5):999-1007. PubMed ID: 23086987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.